Drug Trial Radar · NCT03104699
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Apr 11, 2017
Primary completion
Jun 15, 2022
Study completion Jun 15, 2022
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Conditions
- Advanced Cancer
- Cervical Cancer
Interventions
AGEN2034Drug
Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for BalstilimabTime frame: 21 days
- Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years
- Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)Time frame: Up to 3 years
Locations
44 sites in 9 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
City of Hope
Duarte, California
University of Southern California - Keck School of Medicine
Los Angeles, California
Sylvester Comprehensive Cancer Center
Miami, Florida
Florida Cancer Specialists & Research Institute
Sarasota, Florida
Augusta Oncology
Augusta, Georgia
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Swedish Medical Center-Cherry Hill Campus
Seattle, Washington
Pindara Private Hospital
Benowa, Queensland, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, Brazil
IMIP
Recife, Pernambuco, Brazil
Instituto Nacional de Câncer
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Caridade de Ijuí
Ijuí, Rio Grande do Sul, Brazil
Hospital Mãe de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de São Paulo
São Paulo, São Paulo, Brazil
Hospital Amaral Carvalho
São Paulo, São Paulo, Brazil
Centro Oncológico del Norte
Antofagasta, AN, Chile
Centro De Investigación Del Cancer James Lind
Temuco, AR, Chile
Fundación Arturo López Pérez
Santiago, RM, Chile
Bradford Hill
Santiago, RM, Chile
East-Tallinn Central Hospital
Tallinn, Estonia
North Estonia Medical Centre Foundation
Tallinn, Estonia
Institut Bergonié
Bordeaux, France
Centre Léon Bérard
Lyon, France
L'Institut Paoli - Calmettes
Marseille, France
CHU Hôpital de la Timone
Marseille, France
Centre Antoine-Lacassagne
Nice, France
Hôpital Cochin
Paris, France
Groupe Hospitalier Diaconesses Croix Saint-Simon - Hopital de la Croix Saint-Simon
Paris, France
Clinique Armoricaine de Radiologie
Plérin, France
Institute de Cancerologie de l'Ouest (ICO) - René Gauducheau
Saint-Herblain, France
Institut Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
Szpital Swietego Rafala w Krakowie
Krakow, Lesser Poland Voivodeship, Poland
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.